Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Xcel Energy Inc (XEL) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Xcel Energy IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Xcel Energy Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.99 (market cap $763.64M), while Xcel Energy Inc trades at $73.46 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 60× Ginkgo Bioworks Holdings Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Xcel Energy Inc for 61 Days on average.

DNAXEL
Market Cap
$763.64M$45.82B
Volume
3,204,1776,910,516
Sector
HealthUtilities
52-Week High
$15.83$83.91
52-Week Low
$5.48$69.39
Typical Hold Time
7 Days61 Days
Enterprise Value
$865.59M$84.14B
Dividend Yield
—3.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.

While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.

Xcel Energy Inc

Xcel Energy (XEL) trades at $73.46, up 1.44% today, with a bullish technical signal and consensus analyst target of $90.83 suggesting 24% upside. Recent earnings show mixed beats, with Q2 2026 EPS of $0.93 exceeding expectations. The company maintains solid profitability with a 15.28% net margin and benefits from rising data center power demand, though it faces capital expenditure pressures with a $60 billion investment plan.

The outlook is positive, driven by infrastructure investments and load growth, but risks include high debt levels, wildfire liabilities, and interest rate sensitivity. Wall Street sentiment is bullish with 63% buy ratings, but valuation concerns persist with a P/E of 20.1 above some peers.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
47% Buy53% Sell
Avg holding period · 7 Days
XEL

No sentiment data available yet.

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Xcel Energy Inc

Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan

Read more on XEL →